Loading
Obesity / Overweight / Combined oral contraceptive · Phase 1 Trial
ClinicalTrials.gov · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 drug–drug interaction trial registration examining how eloralintide affects oral contraceptive pharmacokinetics in women with obesity or overweight. No results are yet reported in this registry record. The study is designed to characterize PK parameters (AUC, Cmax, Tmax) over 128 days with three inpatient periods.
Phase 1, Interventional, Single Group, Open label, Basic Science purpose. Obesity, Overweight; Female; age from 18 Years; to 60 Years; accepts healthy volunteers. Intervention: Eloralintide and combined oral contraceptive. Compared with: Combined oral contraceptive (ethinyl estradiol and levonorgestrel). n = 34. 2 sites: United States.
This is a Phase 1 drug–drug interaction trial registration examining how eloralintide affects oral contraceptive pharmacokinetics in women with obesity or overweight. No results are yet reported in this registry record. The study is designed to characterize PK parameters (AUC, Cmax, Tmax) over 128 days with three inpatient periods.
This is a trial registration with NO RESULTS POSTED; no efficacy, safety, or outcome data are available. Phase 1 design addresses pharmacokinetics only; clinical outcomes are not measured.
This early-phase PK interaction study will inform whether eloralintide affects oral contraceptive exposure and may guide future dosing or coadministration guidance. Results are not yet available and clinical safety or efficacy cannot be inferred from this registration alone.
This is a Phase 1 study registration with no reported results, designed to characterize drug–drug interaction pharmacokinetics between an investigational agent and oral contraceptives in a small, defined population.
As stated by the source record.
Quoted from the source exactly as published.
This early-phase PK interaction study will inform whether eloralintide affects oral contraceptive exposure and may guide future dosing or coadministration guidance. Results are not yet available and clinical safety or efficacy cannot be inferred from this registration alone.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07808060). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 34 participants (ESTIMATED). Conditions: Obesity, Overweight. Interventions: DRUG: Eloralintide; DRUG: Combined oral contraceptive. Primary outcome measures: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of Ethinyl Estradiol and Levonorgestrel , Baseline through Day 128; PK: Maximum Concentration (Cmax) of Ethinyl Estradiol and Levonorgestrel , Baseline through Day 128; PK: Time to Maximum Concentration (Tmax) of Ethinyl Estradiol and Levonorgestrel , Baseline through Day 128. Brief summary: The main purpose of this study is to evaluate how eloralintide (LY3841136) effects the way the body processes oral contraceptive in female participants with obesity or overweight. For each participant, the study will last about 8 months and will include 3 stays in the Clinical Research Unit (CRU), each lasting between 6 - 8 nights.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.